Literature DB >> 6387690

The CREST syndrome--successful reduction of pulmonary hypertension by captopril.

P J Prouse, A Lahiri, J M Gumpel.   

Abstract

A patient with severe pulmonary hypertension due to pulmonary arteriolar obliteration complicating a long standing CREST variant of systemic sclerosis showed improvement in cardiac output and exercise tolerance during treatment with captopril, which was discontinued because of persistent systemic hypotension. It is suggested that captopril would have a useful and possible prophylactic effect early in pulmonary hypertension in systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6387690      PMCID: PMC2418051          DOI: 10.1136/pgmj.60.708.672

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Comparative hemodynamic effects of converting enzyme inhibitor and sodium nitroprusside in severe heart failure.

Authors:  T R Vrobel; J N Cohn
Journal:  Am J Cardiol       Date:  1980-02       Impact factor: 2.778

Review 2.  Humoral control of the pulmonary circulation.

Authors:  E H Bergofsky
Journal:  Annu Rev Physiol       Date:  1980       Impact factor: 19.318

3.  The microvascular pathogenesis of scleroderma: an hypothesis.

Authors:  J F Fries
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

4.  Effects of the converting enzyme inhibitor (SQ 20881) on the pulmonary circulation in man.

Authors:  A P Niarchos; A J Roberts; J H Laragh
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

5.  Pulmonary vascular changes in scleroderma.

Authors:  R H Young; G J Mark
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

6.  Reversible ischaemia of right ventricle detected by exercise thallium-201 scintigraphy.

Authors:  A Lahiri; G P Carboni; J W Crawley; E B Raftery
Journal:  Br Heart J       Date:  1982-09

7.  Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma).

Authors:  R Salerni; G P Rodnan; D F Leon; J A Shaver
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

8.  Effects of captopril (SQ 14,225) in a patient with primary pulmonary hypertension.

Authors:  J D Horowitz; J B Brennan; L E Oliver; D Harding; A J Goble; W J Louis
Journal:  Postgrad Med J       Date:  1981-02       Impact factor: 2.401

9.  Clinical course of patients with scleroderma renal crisis treated with captopril.

Authors:  E T Zawada; P J Clements; D A Furst; H A Bloomer; H E Paulus; M H Maxwell
Journal:  Nephron       Date:  1981       Impact factor: 2.847

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.